This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved.

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The list also includes non-hallucinogenic drugs related to hallucinogens, such as non-hallucinogenic serotonin 5-HT2A receptor agonists and non-hallucinogenic ketamine analogues. Cannabinoids, or cannabinoid receptor modulators, are not included in this list. Many of the indications are not for continuous medication therapy but rather are for medication-assisted psychotherapy or short-term use only. The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications.

This list was last comprehensively updated in October 2024. It is likely to become outdated with time.

Under development

Preregistration Midomafetamine (MDMA; "ecstasy") – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – post-traumatic stress disorder, alcoholism, social anxiety in autism – Multidisciplinary Association for Psychedelic Studies (MAPS), Resilient Pharmaceuticals (Lykos Therapeutics)

Phase 3 Deupsilocin (HLP003; HLP-003; CYB003; CYB-003; psilocin-d10; deuterated psilocybin analogue; deuterated psilocin) – serotonin 5-HT2A receptor agonist and psychedelic hallucinogen – major depressive disorder, alcoholism, psychiatric disorders – Helus Pharma (Cybin) Ketamine (AWKN-001, AWKN-P-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – alcoholism, binge-eating disorder, gambling, impulse control disorders, obsessive–compulsive disorder – Awakn Life Sciences Ketamine (HTX-100; NRX-100) – ionotropic glutamate NMDA receptor antagonist – suicidal ideation, mental disorders – NRx Pharmaceuticals Lysergic acid diethylamide (LSD; lysergide; DT120; DT-120; MM120; MM-120) – non-selective serotonin receptor agonist and psychedelic hallucinogen – anxiety disorders, attention-deficit hyperactivity disorder, cluster headache, major depressive disorder, pain – Definium Therapeutics (MindMed) Lysergic acid diethylamide (LSD; lysergide; MB-22001/MB22001) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder, existential distress in cancer patients – MindBio Therapeutics Psilocybin (COMP-360; COMP360) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, anorexia nervosa, bipolar depression, major depressive disorder, post-traumatic stress disorder, somatoform disorders, pervasive child development disorders – COMPASS Pathways Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder, borderline personality disorder – Usona Institute

Phase 2 (R)-Midomafetamine ((R)-MDMA; (R)-methylenedioxymetamfetamine; MM-402) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – pervasive child development disorders/autism spectrum disorder – Definium Therapeutics (MindMed) (R)-Midomafetamine ((R)-MDMA; R-MDMA; EMP-01) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – post-traumatic stress disorder, social phobia – EmpathBio Arketamine ((R)-ketamine; PCN-101) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – depressive disorders – ATAI Life Sciences Blixeprodil (GM-1020; (R)-4-fluorodeschloroketamine; (R)-4-FDCK) – orally active NMDA receptor receptor antagonist – major depressive disorder, bipolar depression, depressive disorders – Gilgamesh Pharmaceuticals Bretisilocin (GM-2505; 5F-MET; 5-fluoro-N-methyl-N-ethyltryptamine) – serotonin 5-HT2A and 5-HT2C receptor agonist, serotonin 5-HT2B receptor antagonist, psychedelic hallucinogen, and serotonin releasing agent – major depressive disorder – Gilgamesh Pharmaceuticals Deudimethyltryptamine (HLP004; HLP-004; CYB004; DMT-d10; deuterated dimethyltryptamine; deuterated DMT; dDMT) – non-selective serotonin receptor agonist and psychedelic hallucinogen – generalized anxiety disorder – Helus Pharma (Cybin) Dimethyltryptamine (DMT; BMND-01/BMND01, BMND-02/BMND02, BMND-03/BMND03) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, fibromyalgia, substance-related disorders – Biomind Labs Esketamine (CLE-100) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder, bipolar depression – Clexio Biosciences Ketamine (Ereska; IN ketamine; ketamine IN; intranasal ketamine; intranasal racemic ketamine; PMI-100, PMI-150, SLS-002, TUR-002) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – post-traumatic stress disorder, suicidal ideation, acute pain, cancer pain – Seelos Therapeutics Ketamine extended-release (R-107, R107) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder – Douglas Pharmaceuticals Ketamine prolonged-release oral (KET-01) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – depressive disorders, neuropathic pain – Ketabon Ketamine/temsirolimus (FREE001) – ionotropic glutamate NMDA receptor antagonist, dissociative hallucinogen, and mTOR inhibitor combination – major depressive disorder – Freedom Biosciences Luvesilocin (RE-104/RE104; FT-104/FT104; 4-HO-DiPT/iprocin prodrug) – serotonin 5-HT2A receptor agonist and psychedelic hallucinogen – postnatal depression – Reunion Neuroscience Mebufotenin (5-MeO-DMT; BPL-002, BPL-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen – alcoholism, major depressive disorder – Beckley Psytech Mebufotenin (5-MeO-DMT; BMND-05/BMND05, BMND-08/BMND08) – non-selective serotonin receptor agonist and psychedelic hallucinogen – Alzheimer's disease, pain – Biomind Labs Mebufotenin (5-MeO-DMT; GH001/GH-001; GH002/GH-002; GH003/GH-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders – GH Research Methylone (MDMC; TSND-201) – serotonin, norepinephrine, and dopamine releasing agent and entactogen – post-traumatic stress disorders, major depressive disorder, CNS disorders – Transcend Therapeutics Midomafetamine (MDMA; "ecstasy") – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – alcoholism – Awakn Life Sciences Midomafetamine/citalopram (MDMA/citalopram) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen followed by a selective serotonin reuptake inhibitor – post-traumatic stress disorder – Tactogen MSP-1014 (psilocin prodrug) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder – Mindset Pharma, Otsuka America Pharmaceutical Non-racemic MDMA (ALA-002; 70–80% (R)-MDMA, 20–30% (S)-MDMA) – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – social anxiety in autism spectrum disorder – PharmAla Biotech OSU-6162 (PNU-9639; PNU-96391; PNU-96391A) – non-hallucinogenic serotonin 5-HT2A receptor partial agonist, dopamine D2 receptor partial agonist, and sigma σ1 receptor ligand (so-called "monoaminergic stabilizer") – bipolar depression, chronic fatigue syndrome, depressive disorders, stroke, subarachnoid hemorrhage, Parkinson's disease – Carlsson Research AB, Pfizer Psilocin – non-selective serotonin receptor agonist and psychedelic hallucinogen – adjustment disorder – Psyence BioMed Psilocin – non-selective serotonin receptor agonist and psychedelic hallucinogen – generalized anxiety disorder – Diamond Therapeutics Psilocybin (low-dose; APEX-52 / 90) – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, anxiety disorders – Apex Laboratories Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – fragile X syndrome – Restart Life Sciences Psilocybin (CYB-001; CYB001; HLP001; INT0052/2020) – non-selective serotonin receptor agonist and psychedelic hallucinogen – mental disorders, major depressive disorder, anxiety disorders – Helus Pharma (Cybin) Psilocybin (MYCO-001, MYCO-003) – non-selective serotonin receptor agonist and psychedelic hallucinogen – post-traumatic stress disorder, anxiety disorders, depressive disorders, headache, substance-related disorders – Mydecine Psilocybin (PEX-010/PEX010) – non-selective serotonin receptor agonist and psychedelic hallucinogen – adjustment disorders, alcoholism, depressive disorders, anxiety disorders – Filament Health Psilocybin (PFN™; TRP-8802, TRP-8803, TRP-8804, TRYP-0082) – non-selective serotonin receptor agonist and psychedelic hallucinogen – binge-eating disorder, fibromyalgia, irritable bowel syndrome, cancer, complex regional pain syndrome, pain – Tryp Therapeutics Psilocybin (Psi-GAD; PSX-001) – non-selective serotonin receptor agonist and psychedelic hallucinogen – generalized anxiety disorder – Incannex Psilocybin (RSTP-1000) – non-selective serotonin receptor agonist and psychedelic hallucinogen – demoralization syndrome – Reset Pharma Psilocybin (SYNP-101; synthetic psilocybin) – alcoholism, obsessive–compulsive disorders, cluster headache, migraine – Ceruvia Lifesciences Xenon (NBTX-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – post-traumatic stress disorder, Alzheimer's disease, irritable bowel syndrome, Parkinson's disease, pervasive child development disorders, panic disorder – Nobilis Therapeutics Zolunicant (18-methoxycoronaridine; 18-MC; MM-110) – α3β4 nicotinic acetylcholine receptor antagonist, other actions – leishmaniasis, opioid-related disorders, substance-related disorders – Definium Therapeutics (MindMed)

Phase 1/2 Dimethyltryptamine (DMT; SPL-026) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder – Small Pharma, Helus Pharma (Cybin) Dimethyltryptamine/harmine (DMT/harmine; RE01) – non-selective serotonin receptor agonist, psychedelic hallucinogen, and monoamine oxidase inhibitor combination – generalized anxiety disorder – reconnect Labs Ibogaine (IBX-210) – various actions and hallucinogen – opioid-related disorders – ATAI Life Sciences/DemeRx Mebufotenin (5-MeO-DMT; RE02) – non-selective serotonin receptor agonist and psychedelic hallucinogen – generalized anxiety disorder – reconnect Labs Psilocybin (PSY-0.1, PSY-0.2, PSY-0.3, PSY-0.4/0.5, PSY-0.6) – non-selective serotonin receptor agonist and psychedelic hallucinogen – substance-related disorders, neurological disorders, opioid-related disorders, psychiatric disorders, traumatic brain injury, cancer, anxiety disorders, bipolar disorders, depressive disorders, eating disorders, and additional unspecified conditions – Revive Therapeutics Psilocybin infusion (ELE-101, ELE-Psilo, ELE-Psilo+) – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder – Eleusis, Beckley Psytech

Phase 1 2-Bromo-LSD (bromolysergide; BOL-148; NYPRG-101) – non-hallucinogenic serotonin 5-HT2A receptor agonist and other actions – cluster headache, migraine – Ceruvia Lifesciences 5-Methoxy-2-aminoindane (5-MeO-AI; MEAI; CMND-100) – serotonin releasing agent and entactogen – alcoholism, cocaine use disorder, metabolic syndrome, obesity – Clearmind Medicine